Form 4: Lemaitre Vascular Director Lawrence J. Jasinski Reports Acquisition of Dividend Equivalent Rights

Director Lawrence J. Jasinski of Lemaitre Vascular Inc. reported the acquisition of dividend equivalent rights related to previously granted stock awards.

Summary

• Lawrence J. Jasinski, a director at Lemaitre Vascular Inc., has reported the acquisition of dividend equivalent rights.
• These rights are associated with previously granted restricted stock unit (RSU) and performance stock unit (PSU) awards.
• The dividend equivalent rights were acquired on December 5, 2024.
• The rights vest proportionately with the underlying stock awards.
• The total dividend equivalent rights acquired are equivalent to 2.3714 shares of common stock.
• The rights are associated with awards granted on December 11, 2021, December 12, 2022, and December 8, 2023.

Sentiment

Score: 7

Explanation: The document is a routine filing related to stock-based compensation. It is neither positive nor negative, but rather a standard reporting requirement. The sentiment is neutral to slightly positive as it indicates alignment of director interests with shareholders.

Industry Context

This is a standard SEC Form 4 filing, which is common for company insiders reporting changes in their beneficial ownership of company securities. It is a routine part of corporate governance and transparency.

Comparison to Industry Standards

• The reporting of dividend equivalent rights is a common practice for companies that grant stock-based compensation.
• Many companies, such as Medtronic, Boston Scientific, and Abbott, also use stock-based compensation and report similar transactions through SEC filings.
• The specific details of the awards and vesting schedules are unique to Lemaitre Vascular's compensation plans, but the reporting mechanism is standard across publicly traded companies.

Stakeholder Impact

• The acquisition of dividend equivalent rights has a minor positive impact on shareholders as it aligns the director's interests with the company's performance.
• The impact on employees, customers, suppliers, and creditors is negligible.

Key Dates

Keywords

dividend equivalent rights, Lemaitre Vascular, director, stock awards, restricted stock units, performance stock units, insider trading, form 4